CYFRA 21-1 Test (Cytokeratin 19 Fragment) – Purpose, Normal Range & High Levels Explained

Overview

The CYFRA 21-1 Test is a tumor-marker blood test that measures small fragments of a protein called cytokeratin 19, which is normally found inside epithelial cells — the cells that line organs and tissues throughout the body.

This test is mainly used in the diagnosis, monitoring, and follow-up of lung cancers, especially non-small-cell lung cancer (NSCLC), and in a few other epithelial cancers such as bladder, cervical, and esophageal cancer.

When epithelial cells become damaged, inflamed, or cancerous, fragments of cytokeratin 19 (called CYFRA 21-1) are released into the bloodstream. Measuring these fragments helps doctors track tumor activity, treatment response, and disease recurrence.

Although it is not used as a standalone diagnostic tool, high or rising CYFRA 21-1 levels often suggest active or progressing cancer, making this test highly valuable in ongoing cancer monitoring.

Where It Is Produced in the Body

Cytokeratin 19 is a structural protein found in the cytoskeleton of epithelial cells.
It provides strength and stability to the cell structure.

CYFRA 21-1 fragments are not synthesized as a hormone or enzyme, but rather appear in the bloodstream when epithelial cells:

• Break down normally, or
• Are destroyed by malignant transformation (cancer activity).

Hence, this marker acts as an indicator of cell damage, especially when levels rise abnormally due to cancer.

Main Functions and Importance

CYFRA 21-1 itself does not play a biological role in the body’s function, but the test is clinically very important for evaluating and managing certain cancers.

🔹 Key Uses:

1. Tumor marker for epithelial cancers — especially those of the lung.
2. Diagnosis and monitoring of non-small-cell lung cancer (NSCLC), particularly the squamous cell carcinoma subtype.
3. Assessing treatment response: falling levels suggest therapy is working.
4. Detecting recurrence — rising levels after treatment can indicate relapse.
5. Used along with other tumor markers, such as:
   • CEA (Carcinoembryonic Antigen)
   • NSE (Neuron-Specific Enolase)
   • Pro-GRP (Pro-gastrin-releasing peptide)
     These combinations improve diagnostic accuracy for lung and other epithelial tumors.

Causes of Low / Negative Levels

Low or normal CYFRA 21-1 levels generally indicate:

• No cancer or successful remission after treatment.
• Early-stage cancer, where the tumor is too small to shed detectable fragments.
• Non-epithelial cancers (because CYFRA 21-1 is specific to epithelial-origin tumors).

Symptoms of Low / Normal Levels:

• Patient may be asymptomatic or showing clinical improvement after therapy.
• Usually a good prognostic sign, meaning the disease is under control.

Causes of High / Positive Levels

High levels of CYFRA 21-1 are commonly associated with lung cancer, particularly NSCLC – squamous cell type, but can also rise in other cancers and some non-cancerous conditions.

🔹 Common Causes:

1. Lung cancers:
   • Non-small-cell lung cancer (especially squamous subtype).
   • Occasionally in adenocarcinoma or large-cell carcinoma.
2. Other epithelial cancers:
   • Bladder cancer
   • Cervical cancer
   • Esophageal cancer
   • Head and neck squamous cell cancers
3. Non-cancerous conditions (false positives):
   • Severe pneumonia or lung infection
   • Chronic obstructive pulmonary disease (COPD)
   • Liver or kidney disease (reduced clearance of protein fragments)

Symptoms of High / Positive Levels

Symptoms depend on the underlying cause, especially if lung cancer is present.

🔹 In Lung Cancer:

• Persistent cough (often with blood-stained sputum)
• Chest pain or discomfort
• Shortness of breath
• Unexplained weight loss and fatigue
• Loss of appetite or low-grade fever

🔹 In Other Conditions:

• Urinary symptoms (bladder cancer)
• Difficulty swallowing (esophageal cancer)
• Lump or sore in the mouth or throat (head and neck cancers)

Reference Range

Persistent or increasing levels during follow-up often indicate disease progression or recurrence.

Sample Type and Collection

• Sample Type: Blood (serum)
• Collection Method: Venipuncture (blood drawn from a vein in the arm)
• Test Method: Performed using immunoassay techniques such as ELISA or electrochemiluminescence.
• Fasting: Not usually required.

Understanding Your Results

Doctors always interpret CYFRA 21-1 together with other tumor markers, imaging (CT scan, PET scan), and biopsy findings for a complete diagnosis.

Test Preparation

• Usually no special preparation is required.
• Inform your doctor about:
  • Current medications or chemotherapy you are receiving.
  • Recent infections, as they may affect results.
• Avoid scheduling the test immediately after a lung infection or surgery, as it can cause false positives.

When to Consult a Doctor

You should see your doctor if you have:

• Persistent cough or breathlessness
• Blood in sputum (hemoptysis)
• Unexplained weight loss or weakness
• Chest pain or recurring lung infections

If you are undergoing cancer treatment, your doctor may order regular CYFRA 21-1 tests every few months to monitor how well therapy is working.

Important Word Explanations

~END~